Tags

Type your tag names separated by a space and hit enter

Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.
J Clin Psychiatry. 2002 Sep; 63(9):796-801.JC

Abstract

BACKGROUND

Treatment with intravenous clomipramine is rapidly effective in some obsessive-compulsive disorder (OCD) patients unresponsive to orally administered serotonin reuptake inhibitors (SRIs). The selective serotonin reuptake inhibitor citalopram is effective for OCD when administered orally. We investigated whether intravenous citalopram would rapidly benefit OCD patients unresponsive to orally administered SRIs.

METHOD

Thirty-nine adult outpatients participated in a 3-week open-label trial of intravenous citalopram. Eligible patients had moderate-to-severe DSM-IV OCD of > or = 1 year's duration, a baseline Yale-Brown Obsessive Compulsive Scale (YBOCS) score > or = 25, and no other active Axis I diagnosis and had failed at least 2 adequate oral SRI trials, excluding citalopram. Intravenous citalopram was administered daily for 21 days, followed by oral citalopram until treatment day 84. Intravenous citalopram was started at 20 mg/day and was increased to 40 to 80 mg/day as tolerated.

RESULTS

Intravenous citalopram was well tolerated even at higher doses (dropout rate = 2.6%). At day 21, 23 (59%) of the 39 patients had YBOCS score decreases of > or = 25%, of whom 4 had decreases of > or = 35%. Twenty-seven patients with YBOCS score decreases of > or = 20% were allowed to continue on treatment with oral citalopram, and by day 84, all had substantial further improvement. All 27 patients also showed significant improvement in several dimensions of quality of life.

CONCLUSION

Intravenous citalopram was safe and rapidly effective in a group of treatment-resistant OCD patients. The early onset of response suggests a means of accelerating OCD symptom relief and predicting response to oral citalopram treatment. Double-blind, double-dummy, placebo-controlled trials of intravenous versus oral citalopram in patients with treatment-resistant OCD are indicated.

Authors+Show Affiliations

Istituto di Neuroscienze, and University of Florence, School of Medicine, Italy. s.pallanti@agora.stm.itNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12363120

Citation

Pallanti, Stefano, et al. "Citalopram Intravenous Infusion in Resistant Obsessive-compulsive Disorder: an Open Trial." The Journal of Clinical Psychiatry, vol. 63, no. 9, 2002, pp. 796-801.
Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry. 2002;63(9):796-801.
Pallanti, S., Quercioli, L., & Koran, L. M. (2002). Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. The Journal of Clinical Psychiatry, 63(9), 796-801.
Pallanti S, Quercioli L, Koran LM. Citalopram Intravenous Infusion in Resistant Obsessive-compulsive Disorder: an Open Trial. J Clin Psychiatry. 2002;63(9):796-801. PubMed PMID: 12363120.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. AU - Pallanti,Stefano, AU - Quercioli,Leonardo, AU - Koran,Lorrin M, PY - 2002/10/5/pubmed PY - 2002/10/12/medline PY - 2002/10/5/entrez SP - 796 EP - 801 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 63 IS - 9 N2 - BACKGROUND: Treatment with intravenous clomipramine is rapidly effective in some obsessive-compulsive disorder (OCD) patients unresponsive to orally administered serotonin reuptake inhibitors (SRIs). The selective serotonin reuptake inhibitor citalopram is effective for OCD when administered orally. We investigated whether intravenous citalopram would rapidly benefit OCD patients unresponsive to orally administered SRIs. METHOD: Thirty-nine adult outpatients participated in a 3-week open-label trial of intravenous citalopram. Eligible patients had moderate-to-severe DSM-IV OCD of > or = 1 year's duration, a baseline Yale-Brown Obsessive Compulsive Scale (YBOCS) score > or = 25, and no other active Axis I diagnosis and had failed at least 2 adequate oral SRI trials, excluding citalopram. Intravenous citalopram was administered daily for 21 days, followed by oral citalopram until treatment day 84. Intravenous citalopram was started at 20 mg/day and was increased to 40 to 80 mg/day as tolerated. RESULTS: Intravenous citalopram was well tolerated even at higher doses (dropout rate = 2.6%). At day 21, 23 (59%) of the 39 patients had YBOCS score decreases of > or = 25%, of whom 4 had decreases of > or = 35%. Twenty-seven patients with YBOCS score decreases of > or = 20% were allowed to continue on treatment with oral citalopram, and by day 84, all had substantial further improvement. All 27 patients also showed significant improvement in several dimensions of quality of life. CONCLUSION: Intravenous citalopram was safe and rapidly effective in a group of treatment-resistant OCD patients. The early onset of response suggests a means of accelerating OCD symptom relief and predicting response to oral citalopram treatment. Double-blind, double-dummy, placebo-controlled trials of intravenous versus oral citalopram in patients with treatment-resistant OCD are indicated. SN - 0160-6689 UR - https://www.unboundmedicine.com/medline/citation/12363120/Citalopram_intravenous_infusion_in_resistant_obsessive_compulsive_disorder:_an_open_trial_ L2 - http://www.psychiatrist.com/jcp/article/pages/2002/v63n09/v63n0908.aspx DB - PRIME DP - Unbound Medicine ER -